Supplemental Table S1. Incidence of adverse events (safety population; n=43)

Parameter	Placebo (n=12)	VX-509 100 mg (n=11)	VX-509 200 mg (n=10)	VX-509 300 mg (n=10)	All VX-509 (n=31)
Total AEs, n	6	13	23	25	61
Patients with ≥1 AE, n %	5 (41.7)	8 (72.7)	8 (80.0)	9 (90.0)	25 (80.6)
Treatment-related AEs, n %	1 (8.3)	3 (27.3)	4 (40.0)	5 (50.0)	12 (38.7)
AEs leading to study discontinuation, n %	0	0	0	2 (20.0)	2 (6.5)
AEs leading to death, n	0	0	0	0	0
Serious AEs, n (%)	0	1 (9.1)	1 (10.0)	0	2 (6.5)
Most common AEs, n (%)					
Diarrhea	0	0	1 (10.0)	2 (20.0)	3 (9.7)
Gastroesophageal reflux disease	0	1 (9.1)	2 (20.0)	0	3 (9.7)
Sinus congestion	0	1 (9.1)	1 (10.0)	1 (10.0)	3 (9.7)

AE, adverse event.